Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer | Nature

We describe netrin-1 upregulation in a majority of human endometrial carcinomas and demonstrate that netrin-1 blockade, using the anti-netrin-1 antibody NP137, is effective both in a mouse model and in patients with endometrial carcinomas.

Download PDF Subjects Endometrial cancer Translational research Tumour heterogeneity Abstract Netrin-1 is upregulated in cancers as a protumoural mechanism 1 . Here we describe netrin-1 upregulation in a majority of human endometrial carcinomas (ECs) and demonstrate that netrin-1 blockade, using an anti-netrin-1 antibody (NP137), is effective in reduction of tumour progression in an EC mouse model. We next examined the efficacy of NP137, as a first-in-class single agent, in a Phase I trial comprising 14 patients with advanced EC. As best response we observed 8 stable disease (8 out of 14, 57.1

related reading

• Neoadjuvant immune checkpoint blockade in high-risk resectable melanomanature.com
• Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
• Cancer cells educate natural killer cells to a metastasis-promoting cell state - PubMedpubmed.ncbi.nlm.nih.gov
• Epigenetic regulation during cancer transitions across 11 tumour typesnature.com
• Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review - PMCpmc.ncbi.nlm.nih.gov
• Summing up cancer stem cellsnature.com
• Endometrioid carcinomapathologyoutlines.com
• Home - DynaMeddynamed.com
• Multiband mucosectomy for advanced dysplastic lesions in the upper digestive tractncbi.nlm.nih.gov
• Nasopharyngeal Carcinoma(Archived) - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
• Lopez-Colon.pdffredhutch.org
• The current state of the art and future trends in RAS-targeted cancer therapiesnature.com